José Manuel Cameselle-Teijeiro

15PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersMacromolecular materialsGene expression (incl. microarray and other genome-wide approaches)Molecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 07, 2026
MLH1 promoter methylation, mismatch repair and intestinal differentiation markers in papillary thyroid carcinoma: real-world evidence from Galicia (Northwest Spain).

|Jul 01, 2025
Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain).

Ihab Abdulkader-Nallib, José Manuel Cameselle-Teijeiro, Iván Lesende-Rodríguez

|Apr 02, 2025
Adrenal mixed corticomedullary tumors: report of a case with molecular characterization and systematic review.

Edurne Pérez-Béliz, Benjamín Alfonso Thorpe-Plaza, Everardo Josué Díaz-López

|Mar 13, 2025
New Insights into the Clinical Characterization of SDHAF2-related Familial Paraganglioma Syndrome.

Antia Fernandez-Pombo, Zulema Nogareda-Seoane, Jose Manuel Cameselle-Teijeiro

|Jul 11, 2024
Author Correction: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.

Joana S Rodrigues, Miguel Chenlo, Susana B Bravo

|May 14, 2024
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.

Joana S Rodrigues, Miguel Chenlo, Susana B Bravo

Pageof 3

Frequent Collaborators

4 joint publications

Susana Belén Bravo-López

3 joint publications

Clara V Alvarez

3 joint publications

Miguel Chenlo

2 joint publications

Román González-Prieto